Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02025023 · ClinicalTrials.gov registry record · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
A Phase 3 study of Chalazion, sponsored by University of Washington.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT02025023: Recruiting Phase 3 study of Chalazion, sponsored by University of Washington.
NCT02025023 is a Phase 3 study of Chalazion that is actively recruiting participants, run by University of Washington. The registered enrollment target is 120 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02025023, a Phase 3 study of Chalazion, is actively recruiting participants, sponsored by University of Washington.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
Local injection of 5-fluorouracil into a chalazion (stye) is as effective as local injection of triamcinolone (steroid) and incision and curettage for treatment of chalazia.
Conditions Studied
Interventions
- DRUG 5-fluorouracil Injection
- DRUG Triamcinolone Acetonide
- PROCEDURE Incision and Curettage
- DRUG Triamcinolone Acetonide/5-fluorouracil mixture
Study Locations (1)
Washington
- University of Washington Eye Institute at Harborview - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2013-12 |
| Est. Completion | 2026-07 |
| Phase | Phase 3 |
What NCT02025023 shows while recruiting
NCT02025023 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Chalazion appearing as the primary indexed condition, and to 4 interventions - of which 5-fluorouracil Injection is the first listed.
NCT02025023 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT02025023 about?
NCT02025023 is a clinical study titled "Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study". Local injection of 5-fluorouracil into a chalazion (stye) is as effective as local injection of triamcinolone (steroid) and incision and curettage for treatment of chalazia.
What is the current status of trial NCT02025023?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 120 participants. The study started on 2013-12. Estimated completion is 2026-07.
What conditions does trial NCT02025023 study?
This clinical trial studies the following conditions: Chalazion.
What interventions are being tested in trial NCT02025023?
The interventions under investigation include: 5-fluorouracil Injection (DRUG), Triamcinolone Acetonide (DRUG), Incision and Curettage (PROCEDURE), Triamcinolone Acetonide/5-fluorouracil mixture (DRUG).
Who is sponsoring clinical trial NCT02025023?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02025023 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chalazion
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02025023's enrollment target sits among peer trials
120 1620th of 2000 higher than 361 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
- NCT02164409 · 120 participants
Changes Associated With H. Pylori and Gastric Carcinogenesis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia